The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells

Véronique Dartois

doi:10.1038/nrmicro3200

The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells

Véronique Dartois

Center for Discovery and Innovation

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technology could be used to design optimized multidrug regimens.

Original language	English
Pages (from-to)	159-167
Number of pages	9
Journal	Nature Reviews Microbiology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1038/nrmicro3200
State	Published - Mar 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Microbiology
General Immunology and Microbiology
Infectious Diseases

Access to Document

10.1038/nrmicro3200

Cite this

@article{0a71291434a44387bc0d029c1a099a4a,

title = "The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells",

abstract = "For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technology could be used to design optimized multidrug regimens.",

author = "V{\'e}ronique Dartois",

note = "Funding Information: The author thanks T. Dick, J. Sarathy and B. Prideaux for many stimulating discussions. V.D. is funded by the Tuberculosis Drug Accelerator program of the Bill and Melinda Gates Foundation and grant R01AI106398-01 from the US National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID).",

year = "2014",

month = mar,

doi = "10.1038/nrmicro3200",

language = "English",

volume = "12",

pages = "159--167",

journal = "Nature Reviews Microbiology",

issn = "1740-1526",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - The path of anti-tuberculosis drugs

T2 - From blood to lesions to mycobacterial cells

AU - Dartois, Véronique

N1 - Funding Information: The author thanks T. Dick, J. Sarathy and B. Prideaux for many stimulating discussions. V.D. is funded by the Tuberculosis Drug Accelerator program of the Bill and Melinda Gates Foundation and grant R01AI106398-01 from the US National Institutes of Health-National Institute of Allergy and Infectious Diseases (NIH-NIAID).

PY - 2014/3

Y1 - 2014/3

N2 - For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technology could be used to design optimized multidrug regimens.

AB - For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets. However, most currently used anti-tuberculosis drugs were introduced into clinical use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies. In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technology could be used to design optimized multidrug regimens.

UR - https://www.scopus.com/pages/publications/84894068321

U2 - 10.1038/nrmicro3200

DO - 10.1038/nrmicro3200

M3 - Article

C2 - 24487820

SN - 1740-1526

VL - 12

SP - 159

EP - 167

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

IS - 3

ER -

The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this